CytomX Therapeutics Inc
CTMX
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
106.8% upsideUndervalued by 106.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $474.43 Million |
|---|---|
| Enterprise Value | $466.33 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.15 |
| Beta | 2.09 |
| Outstanding Shares | 177,273,000 |
Return
| Return on Equity | -18.48% |
|---|---|
| Return on Assets | -16.46% |
| Return on Invested Capital | -19.87% |
Valuation & Multiples
| P/E Ratio | -8.17 |
|---|---|
| PEG | 4.6 |
| Price to Sales | - |
| Price to Book Ratio | 3.15 |
| Enterprise Value to Revenue | 13.12 |
| Enterprise Value to EBIT | -7.21 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6740▲ 61.80% |
|---|---|
| Total Calls | 2,599,301▲ 102.44% |
| Total Puts | 1,751,800▲ 2339.83% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 140.04%▲ 52.74% |
|---|---|
| Total Invested | $907.86M▲ 47.93% |
| Investors Holding | 191▲ 61.00% |
ESG Score
No data
About CytomX Therapeutics Inc
CEO: Sean McCarthy Relevant Senate Committees
Controls Medicare and Medicaid pricing and reimbursement policies, which are critical for the commercial viability of new oncology drugs.
Sets the specific funding levels for the FDA and NIH, directly impacting the speed of drug reviews and the availability of research grants.
Directly oversees the FDA and NIH; members have non-public insights into drug approval processes and federal research priorities.
Oversees intellectual property and patent law, which are the primary value drivers for biopharmaceutical companies like CytomX.
Highly relevant as cancer therapies primarily target the elderly; its investigations into drug pricing create significant headline and regulatory risk.